<i>Schistosoma mansoni</i> infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade

Shousha, Hend Ibrahim; Abdelaziz, Ashraf Omar; Nabeel, Mohamed Mahmoud; Omran, Dalia; Abdelmaksoud, Ahmed Hosni; Elbaz, Tamer; Salah, Ayman; Harb, Shady Tarek ElGhazaly; Hosny, Karim Adel; Osman, Ayman M. A.; Atef, Mira; Gaber, Abdelazez; Yosry, Ayman; Lithy, Rania

doi:10.1080/20477724.2021.1975081

Cited by 8 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we did not investigate hepatitis B infection among S. japonicum patients with liver cancer. However, the results showed that both the peak prevalence rate and peak mortality occurred in the sixth decade of life in S. japonicum patients with liver cancer, which was consistent with Shousha’s research ( 15 ).…”

Section: Discussionsupporting

confidence: 90%

The prevalence rate, mortality, and 5-year overall survival of Schistosoma japonicum patients with human malignancy

Liu,

Ju,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOnly a few studies have focused on the association between Schistosoma japonicum and human malignancy. The aim of this study was to update the prevalence rate, mortality, and 5-year overall survival of S. japonicum patients with human malignancy.MethodsFrom January 20, 2018, to January 31, 2021, 5,866 inpatients were included in the study. A total of 656 S. japonicum patients with malignancy were identified. Cases were stratified by gender and age groups. The cancer sites, prevalence rate, mortality, and 5-year overall survival of the patients were reported. The S. japonicum patients with malignancy were further divided into a non-digestive system tumor group (n = 309) and a digestive system tumor group (n = 347), including those with cancer in the esophagus, stomach, colon, rectum, liver, gallbladder, bile duct, or pancreas. Chi-squared test and odds ratio with confidence intervals were performed between these two groups.ResultsLung cancer was found the most common malignancy, accounting for 18.6% of all malignancies, followed by colorectal, stomach, liver, and gallbladder cancers. These five leading malignancies accounted for approximately 61.8% of all cases. Colorectal cancer was the leading cause of malignancy death, followed by lung, stomach, gallbladder, and liver cancers. These five leading causes of death accounted for approximately 55.6% of all death cases. Statistical significance was found in the prevalence rate between S. japonicum and non-S. japonicum patients with/without digestive system tumor (p < 0.001). The odds ratio of S. japonicum patients with digestive system tumors was 1.6 (95%CI: 1.4–1.9).ConclusionS. japonicum contributes to a significant prevalence and mortality in digestive system tumors, including colorectal, stomach, liver, and gallbladder cancers.

show abstract

Section: Discussionsupporting

confidence: 90%

The prevalence rate, mortality, and 5-year overall survival of Schistosoma japonicum patients with human malignancy

Liu,

Ju,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It is speculated that parasitic infections may play a role in carcinogenesis due to changes in the host's inflammatory response. Schistosomiasis has been associated with the development not only of HCC, but also colorectal cancer, prostate cancer and giant follicular lymphomas 54 . It is known that liver schistosomiasis likely potentiates hepatic injury when coinciding with hepatitis B virus and hepatitis C virus (HCV) infections 10,55 .…”

Section: Schistosomiasis and Hepatocellular Carcinomamentioning

confidence: 99%

Insights on the Pathophysiology of the Progression to Decompensated Hepato-Splenic Schistosomiasis

Carvalho¹

2023

MRAJ

View full text Add to dashboard Cite

Hepato-splenic schistosomiasis is the most important etiology of non-cirrhotic portal hypertension. It represents a particular type of chronic liver disease, which presents unique characteristics that differentiate it from those found in cirrhosis. The relative preservation of liver parenchyma despite portal fibrosis was thought to yield a more benign course of hepato-splenic schistosomiasis in terms of synthetic dysfunction and late decompensations. However, a wide range of immunologic and vascular modifications is responsible for an otherwise progressive liver disease resulting in decompensated condition frequently undistinguished from hepatic cirrhosis. A predominant Th2 immune response type, in which a fibrogenic profile of cytokines and interleukins such as IL-13, provides an immune-inflammatory background that favors fibrosis and its progression. Intra-hepatic vascular changes with portal vein branch derangement and abnormal vascular proliferation also contribute to continued disarray of the liver architecture resulting in decompensated disease frequently undistinguished from hepatic cirrhosis. This article will review immunologic and pathophysiological aspects of hepato-splenic schistosomiasis that might explain disease progression and severity.

show abstract

Schistosoma mansoni infection and hepatocellular carcinoma: a comorbidity study

Allam,

Farag,

Shehab

et al. 2024

J Parasit Dis

View full text Add to dashboard Cite

Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade

Cited by 8 publications

References 32 publications

The prevalence rate, mortality, and 5-year overall survival of Schistosoma japonicum patients with human malignancy

The prevalence rate, mortality, and 5-year overall survival of Schistosoma japonicum patients with human malignancy

Insights on the Pathophysiology of the Progression to Decompensated Hepato-Splenic Schistosomiasis

Schistosoma mansoni infection and hepatocellular carcinoma: a comorbidity study

Contact Info

Product

Resources

About